drugset / Trial / NCT01776437

Study of BMN 673, a PARP Inhibitor, in Healthy Adult Male Volunteers

NCT01776437

Phase 1 Completed 18 enrolled Pfizer
RandomizedCrossoverOpen-labelOther

Summary

This is a randomized, 2-period, 2-sequence crossover study to evaluate the effect of food on the relative bioavailability of BMN 673 during fasting and fed conditions in healthy male subjects.

Timeline

Start
2013-02
Primary completion
2013-05
Completion
2013-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Talazoparib Small molecule 500 ug

Indications

No indication recorded.